Current results of pelvic perfusion for non-resectable relapsing of pelvic cancer.

Twenty-eight patients affected by non-resectable pelvic recurrence of a primary pelvic malignant neoplasm were treated by isolated pelvic perfusion, at mean hyperthermia, with different drugs, chosen taking into account tumor chemosensitivity. All patients had been previously treated. Four complete and six partial responses were observed; nine patients had stable disease and four other patients were non-responders and died due to progression in a few months.

Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan.

Background: 24-60% of patients with soft tissue sarcoma shows local recurrences after treatment of the primary tumor. The event is associated with a high incidence of macroscopic or microscopic metastases and a poor survival. Our goal is to preserve a patient's functional limb by treating such cases with isolated limb perfusion (ILP) with recombinant human tumor necrosis factor alpha (rHu TNF-alpha) and melphalan, which have demonstrated a potent antitumor activity in vivo and in vitro studies.

Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer.

Between May 1990 and December 1995, 16 patients with primary or recurrent unresectable rectal cancer were treated by isolated pelvic perfusion. All patients had been previously treated and were considered unsuitable for surgery or further systemic chemotherapy or radiotherapy. The treatment was based on a perfusion lasting 90 min at 40.